OIS (Ophthalmic Imaging Systems) gains interest from new investor
This article was originally published in Clinica
Executive Summary
S2 Partners, a Minnesota-based institutional investor, has purchased over half a million shares in Ophthalmic Imaging Systems (OIS) from MediVision, OIS' major shareholder. The 550,000 shares were bought at a price of $1.35 per share, $0.25 higher than the midpoint in OIS' trading range in the past year, according to a report by the Sacramento Business Journal.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.